MYP_082708
Ravulizumab
Anticancer
Immunology
▸
Immune modulation
▸
Immunomodulatory activity
Standard
214 amino acids
C1016H1587N271O334S6
Standard
DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
23134.47 Da
5.72
-2.10
-2.53
-0.0098
-0.38
0.58
0.01
45.61
70.61
0.0888
24410.00
24660.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Amino Acid Composition
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
RECORD: Rec_0197984
VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Monoclonal antibody
32630
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Immunomodulatory
The mean (SD) terminal elimination half-life of ravulizumab in patients with PNH was recorded as 49.7 (8.9) days [FDA Label].
RECORD: Rec_0334922
VERIFIED: NO
Provenance & Taxonomy
not reported [other]
Enzyme
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer
Immunomodulatory
The mean (SD) terminal elimination half-life of ravulizumab in patients with PNH was recorded as 49.7 (8.9) days [FDA Label].
RECORD: Rec_0364222
VERIFIED: NO
Provenance & Taxonomy
not reported [other]
Enzyme
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Immunomodulatory
The mean (SD) terminal elimination half-life of ravulizumab in patients with PNH was recorded as 49.7 (8.9) days [FDA Label].